Connected With Latham

Episode 132 details French and European transparency rules for healthcare companies.

21 min Listen to the original Episode page
Healthcare RegulationFranceTransparencyCompliancePharmaceuticalsMedical DevicesEuropeUK

Summary

Nicole Liffrig Molife outlines mandatory French transparency laws requiring pharmaceutical and medical device companies to disclose payments to healthcare beneficiaries on the Transparent Santé website. The episode explains that jurisdiction is based on the beneficiary's location, capturing foreign companies, and defines beneficiaries broadly to include influencers and software designers. Reporting covers agreements, remunerations, and benefits with a low 10-euro de minimis threshold and semi-annual deadlines. The discussion contrasts France's legal mandates with self-regulation in the UK and industry-led approaches in Germany and Spain.

Key takeaways

  1. 1
    really matters: it doesn't matter where you're headquartered. So you don't have to be based or market products in France. If you're entering into agreements with or giving remunerations or benefits to healthcare beneficiaries in France, you're in scope.

    Unidentified speaker (speaker_1) · 2:43

  2. 2
    That's right, Nicole. Companies acting on behalf of entities that manufacture or commercialize Commercialized health products are covered too. So that can include other entities in the same group, say a holding company. or a research entity, even if they don't make or sell health products themselves. And it also includes external providers acting in the name and on behalf of the company.

    Unidentified speaker (speaker_1) · 3:04

  3. 3
    There is, but it's very low. 10 euros. taxes included. So there's really very little wiggle room.

    Unidentified speaker (speaker_1) · 6:24

  4. 4
    Through the professional portal of the Transparent Santé website, which is overseen by the French health ministry. And here's a practical point for US companies disclosures must be made in French.

    Unidentified speaker (speaker_1) · 10:31

Episode sections

  1. 0:03 – 2:23

    Introduction and Scope of French Transparency Rules

    Nicole Liffrig Molife introduces the episode focusing on European transparency requirements, starting with France. Speaker 1 explains that French rules are mandatory law for pharmaceutical and medical device companies, requiring disclosure on the Transparent Santé website, regardless of the company's headquarters location.

  2. 2:23 – 6:02

    Reporting Obligations and Beneficiaries in France

    Speaker 1 details that reporting applies to companies manufacturing or commercializing health products in France, including group entities and external providers. The definition of 'healthcare beneficiaries' is broad, covering professionals, institutions, patient associations, influencers, and software designers.

  3. 6:02 – 9:51

    Disclosure Requirements: Agreements, Remunerations, and Benefits

    The discussion covers three buckets: agreements (disclosed by half-year with extensive details), remunerations (amounts paid rounded to the nearest euro), and benefits (in-kind or cash). A de minimis threshold exists but is very low at 10 euros.

  4. 9:51 – 12:30

    French Deadlines, Publication, and Penalties

    France requires semi-annual reporting with deadlines of September 1st and March 1st for submission, and October 1st and April 1st for publication. Data remains public for five years. Violations can result in criminal fines up to 225,000 euros and other sanctions.

  5. 12:30 – 20:38

    European Landscape and UK Self-Regulation

    Speaker 1 advises mapping operations across Europe, noting that some countries use legal mandates (France, Belgium) while others rely on industry associations (Germany, Spain). The UK currently uses self-regulation via the ABPI code, with no current legislative framework, though guidance is being developed.

Claims worth verifying

France has a mandatory transparency regime for pharmaceutical and medical device companies requiring disclosure on the Transparent Santé website.

Unidentified speaker (speaker_1) ·1:37

How to verify: French Ministry of Health regulations; search 'Transparent Santé website' and 'Loi Hôpital, Patients, Santé et Territoires' or 'Loi Kouchner' for statutory text. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

French transparency rules apply to companies entering into agreements with healthcare beneficiaries in France, regardless of where the company is headquartered.

Unidentified speaker (speaker_1) ·2:43

How to verify: French Public Health Code (Code de la santé publique) Article L111-14 and subsequent decrees defining territorial scope. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The de minimis threshold for reporting in France is 10 euros, taxes included.

Unidentified speaker (speaker_1) ·6:24

How to verify: French Ministry of Health guidelines on transparency declarations; verify current threshold on 'transparence.sante.gouv.fr'. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Disclosures in France are due by September 1st for the first half of the year and March 1st for the second half.

Unidentified speaker (speaker_1) ·9:51

How to verify: French Public Health Code Article L111-14-1; check official government portal for reporting deadlines. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Companies that knowingly violate French transparency requirements can face criminal fines of up to 225,000 euros.

Unidentified speaker (speaker_1) ·11:20

How to verify: French Penal Code and Public Health Code provisions on sanctions for non-compliance with transparency obligations. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The UK currently has no legislative framework regulating transparency for pharmaceutical companies, relying instead on self-regulatory codes like the ABPI code.

Unidentified speaker (speaker_1) ·14:44

How to verify: UK Department of Health and Social Care (DHSC) publications; Association of the British Pharmaceutical Industry (ABPI) Code of Ethics. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) requires members to disclose certain reportable activities every year.

Unidentified speaker (speaker_1) ·13:34

How to verify: EFPIA Disclosure Code; check EFPIA website for member obligations and annual reporting requirements. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

In the UK, disclosures under the ABPI code are published on the Disclosure UK website and remain public for three years.

Unidentified speaker (speaker_1) ·16:50

How to verify: Prescription Medicines Code of Practice Authority (PMCPA) website; ABPI Code of Ethics enforcement procedures. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the specific definition of 'healthcare beneficiary' under the French Public Health Code to determine if your organization's partners fall within scope.
  • Check the Transparent Santé website portal requirements for language and data formatting to ensure compliance with French submission standards.
  • Review the French Public Health Code for the exact de minimis threshold and reporting obligations for external providers and holding companies.
  • Compare the French semi-annual reporting deadlines (Sept 1/Mar 1) against your internal fiscal calendar to adjust reporting workflows.
  • Investigate the current status of UK ABPI code updates and any proposed legislative frameworks that may replace self-regulation.
  • Assess the scope of 'agreements' disclosure requirements, including the level of detail needed for contracts with influencers and software designers.
  • Confirm if your organization's entities in Belgium or Germany are subject to similar legal mandates or industry association codes.
  • Review the potential criminal fines (up to 225,000 euros) and sanctions for non-compliance under French law.
Full transcriptexpand

0:03Nicole Liffrig Molife: Hello, and welcome to Connected with Latham, where we discuss ideas, legal developments, and business trends shaping the global economy. I'm Nicole Liffrig Molife, Counsel in the Healthcare and Life Sciences practice in our Washington, D.C. office. This is episode two of our series, Shining a Light on the Sunshine Act and Transparency Requirements. Last time we covered the U.S. Physician Payments Sunshine Act. So if you want a primer on All Things Sunshine Act, check out that episode. Today we're crossing the Atlantic. If your life sciences company works with healthcare professionals, healthcare Care organizations, or patient organizations in Europe, this one's for you. We'll start in France, which has one of the most detailed transparency regimes out there. And then we'll take a quick tour of the rules of the road in a few other European countries. Joining me today is my friend and colleague Evelyn Van

1:07Kimulen, a partner in our Paris and Brussels offices. And Evelyn is also the vice chair. of our healthcare and life sciences practice. Evelyn, thank you so much for being here today.

1:21Unidentified speaker (speaker_1): Thank you for having me, Nicole. I'm excited to walk listeners through the requirements in France and elsewhere in Europe so they have a solid footing on European transparency rules.

1:30Nicole Liffrig Molife: Let's jump right in. Evelyn, for anyone hearing about the French rules for the first time, would you give us a quick rundown?

1:37Unidentified speaker (speaker_1): Sure. First thing to know, in France, this is the law, not just a voluntary industry code. So pharmaceutical and medical device companies have to comply with these transparency or sunshine requirements. They are required to disclose certain information on a public website called the Transparent Santé website, where anyone can access and search it.

1:59Nicole Liffrig Molife: So just like in the US, transparency is the goal. But is that approach consistent across Europe?

2:06Unidentified speaker (speaker_1): Exactly. Transparency is the common goal, but the rules aren't the same everywhere. And every country has its own requirements.

2:12Nicole Liffrig Molife: Right. So let's start with the nuts and bolts of the requirements in France, because they're pretty extensive. First up, who do the French rules apply to?

2:23Unidentified speaker (speaker_1): They apply to companies that manufacture or commercialize health products. including pharmaceuticals and medical devices, or that provide related services and that enter into agreements with or provide remunerations or benefits to healthcare actors based in France. We'll call those healthcare beneficiaries, and I'll unpack that term in a bit. But here's the part that really matters: it doesn't matter where you're headquartered. So you don't have to be based or market products in France. If you're entering into agreements with or giving remunerations or benefits to healthcare beneficiaries in France, you're in scope.

2:57Nicole Liffrig Molife: That's a very helpful watch out for our listeners. And Evelyn, I understand the rules reach beyond the manufacturer itself.

3:04Unidentified speaker (speaker_1): That's right, Nicole. Companies acting on behalf of entities that manufacture or commercialize Commercialized health products are covered too. So that can include other entities in the same group, say a holding company. or a research entity, even if they don't make or sell health products themselves. And it also includes external providers acting in the name and on behalf of the company.

3:24Nicole Liffrig Molife: So here's a pro tip for our listeners: map out your organizational structure and your external vendors and providers, and then designate one entity to take charge of that publication and reporting and set up clear procedures. for collecting information across all group entities and your external providers. That way, you'll end up with one consolidated report.

3:48Unidentified speaker (speaker_1): That's a great tip, Nicole, and that can save a lot of headaches.

3:51Nicole Liffrig Molife: Now that we know who has to report, let's talk about who they're reporting on. In the US, we talked about covered recipients, teaching hospitals, and immediate family. members. Evelyn, how

4:04Unidentified speaker (speaker_2): does France compare?

4:06Unidentified speaker (speaker_1): So France casts a much wider net. Companies have to report agreements with and remunerations or benefits given to healthcare beneficiaries. And there are several categories of such healthcare beneficiaries. First, there are individuals and entities that provide healthcare services, such as healthcare professionals. So that includes physicians, pharmacists, nurses, midwives, but also opticians, physiotherapists, childcare assistants, dental assistants, and so on. But it also includes associations of healthcare professionals, students intending to become healthcare professionals and their student groups and associations, healthcare institutions, academies, nonprofit associations like foundations and learned societies, and advisory boards in the healthcare sector, as well as legal entities. that provide or participate in the training of healthcare professionals like universities, university hospitals, and continuing medical education organizations. And then similar to the US Bonafide employee exclusion, you don't need to disclose remuneration paid to Bonafide healthcare professionals who work as employees of companies.

5:10Nicole Liffrig Molife: That's a really helpful breakdown. And that's already a very broad net. But I know it doesn't stop here with healthcare professionals, institutions, and academic entities. Who else counts as a healthcare beneficiary in France?

5:25Unidentified speaker (speaker_1): Yeah, you're right. The list also includes patient associations, radio and television broadcasters and publishing companies, including the scientific and the medical press, influencers, so people who in the media or on social media present. health products in order to influence the public, as well as designers of software for prescribing and dispensing health products.

5:45Nicole Liffrig Molife: Wow. Patient associations, influencers, and more. That's quite the list of reportable individuals and organizations.

5:53Unidentified speaker (speaker_1): Exactly. It's a very, very broad net.

5:56Nicole Liffrig Molife: That's good to know. So, Evelyn, let's get into the what. What has to be reported? So

6:02Unidentified speaker (speaker_1): at a very high level, the French rules cover two main types of activities. First, entering into agreements with healthcare beneficiaries. And second, providing remunerations and or benefits to them. In practice, that breaks down into three buckets agreements, remunerations, and benefits.

6:20Nicole Liffrig Molife: And is there a de minimis threshold like in the US?

6:24Unidentified speaker (speaker_1): There is, but it's very low. 10 euros. taxes included. So there's really very little wiggle room.

6:31Nicole Liffrig Molife: That's an important takeaway. So you basically need to track almost everything. Let's take those buckets one at a time, starting with agreements.

6:40Unidentified speaker (speaker_1): Sure. So for agreements with healthcare beneficiaries, companies have to disclose them for each calendar half year, and the list of reportable data is extensive. It covers the parties. the subject matter, such as research or speaking events, the monetary value, and more. So let's break that down even more. First, the parties. Companies have to disclose the company's own corporate name, purpose and headquarters, plus the identity of the beneficiary. For a healthcare professional, that's things like name, profession, professional address, and registration number. For an influencer, it's the name under which they exit exercise their influence. Then the subject matter, using the categories that are set out by law. For example, scientific research, partnership, sponsorship, market study, consultancy, scientific expert, or speaker. Then we go on with the monetary value. That's the total amount foreseen when the agreement is signed, the date of signature, and the end date of the agreement if it's known. The direct and final beneficiary, for example, where there is subcontracting, and event details such as the organizer, name, date, and place if the agreement relates to a scientific or a promotional event.

7:50Nicole Liffrig Molife: That's quite the list. And one important thing to flag for our listeners, if the agreement is amended, Recommended, you'll need a revised declaration and disclosure, right?

8:01Unidentified speaker (speaker_1): Yeah, that's right, Nicole. It's also important to keep an eye on purchase agreements for goods or services, like those between life sciences companies, wholesalers, and pharmacies, because those may be out of scope.

8:11Nicole Liffrig Molife: That's a great tip. So, listeners, identify your purchase agreements and evaluate whether they're in or out of scope. So now on to the second bucket. What about remuneration?

8:25Unidentified speaker (speaker_1): Remuneration Remunerations is provided to healthcare beneficiary. beneficiaries have to be disclosed too. That includes the beneficiary's identity, the amount actually paid, rounded to the nearest euro, the date of each payment, and the calendar half year in which it was received.

8:38Nicole Liffrig Molife: And for the third and final bucket, what about benefits?

8:43Unidentified speaker (speaker_1): Right. So any direct or For indirect benefit, in kind or in cash, has to be disclosed. Benefits in kind, including include gifts, free medical equipment, and hospitality like meals and hotels. Benefits in cash include, for example, commission fees, rebates, discounts, and reimbursement of costs. And for each benefit, companies have to disclose the beneficiary's identity, the amount, the nature of the benefit, the date, and the calendar half-year. half year.

9:11Nicole Liffrig Molife: That's quite a range. And here's one that catches people's. people off guard: indirect benefits. The direct beneficiary should let the company know about possible indirect beneficiaries, like relatives or groups the beneficiary may belong to. Sound familiar? It reminds me of the immediate family member concept we discussed for U.S. ownership interests.

9:35Unidentified speaker (speaker_1): Oh, yes, it it does, Nicole. Sounds very familiar. You're You really sure? show how sweeping the rules can be.

9:40Nicole Liffrig Molife: So let's turn to something really important: timing. Evelyn, in the US, everyone has March 31st circled on their calendar. What are their key dates in France?

9:51Unidentified speaker (speaker_1): Great question. And the big difference is that France reports by semester, so twice a year, not annually. Disclosures are due by September 1st at the latest for agreements. signed, remunerations paid, and benefits granted in the first half of the current year. And then by March 1st of the following year at the latest for the second half of the previous year.

10:13Nicole Liffrig Molife: So two deadlines a year for that sticky note.

10:16Unidentified speaker (speaker_1): Exactly. And then the information is published on the Transparence Santé website by October 1st for the first semester, and by April 1st of the next year. for the second semester.

10:28Nicole Liffrig Molife: And how do companies actually make these disclosures?

10:31Unidentified speaker (speaker_1): Through the professional portal of the Transparent Santé website, which is overseen by the French health ministry. And here's a practical point for US companies disclosures must be made in French. So that's definitely also one for the sticky note. Once published, the information is searchable by company or by healthcare beneficials. beneficiary and it stays public for five years.

10:53Unidentified speaker (UNKNOWN): I

10:53Nicole Liffrig Molife: think there's a pro tip here for our listeners. Plan ahead and make sure your systems can capture those expansive French categories and translate it in French. Evelyn, what if a company needs to fix something after it files its report?

11:09Unidentified speaker (speaker_1): Good news there. Companies can modify, delete, or otherwise change their disclosures at any time. before or after publication.

11:16Nicole Liffrig Molife: That's helpful. What happens if a company gets it wrong?

11:20Unidentified speaker (speaker_1): Well, the stakes are real because companies that knowingly violate the transparency requirements can face a criminal fine of up to 225,000 euros. And there can also be additional sanctions like a ban on bidding for public tenders, suspension of business activities, or temporary or permanent closure of facilities. And importantly, individuals can be sanctioned too. Think public communication of the sentence, being barred from a public function or a commercial or industry profession, or being prohibited from commercializing, importing, and marketing health products. These sanctions are not that common, but they are being granted in several occasions.

11:57Nicole Liffrig Molife: Those are some serious consequences. So here's a key takeaway. If you're your company interacts with healthcare professionals, healthcare organizations in France, set up your tracking processes early and make sure they capture every transfer of value, even the very small ones. The French rules are complex and detailed, so it pays to get ahead of them. Now, Evelyn, let's look beyond France. What should companies keep in mind? about transparency requirements elsewhere in Europe?

12:30Unidentified speaker (speaker_1): My top tip: start with a map. Identify every country where you do business and have relationships with healthcare professionals, healthcare organizations, and patient organizations. That matters because the rules vary from country to country. So some countries, like France and Belgium, In have transparency requirements written into law, while others rely on voluntary reporting tied to membership in national industry associations.

12:53Nicole Liffrig Molife: That's a lot to keep track of. So just to clarify, even in countries without a reporting law, an industry association may still require its members to report. Is that right?

13:05Unidentified speaker (speaker_1): That's absolutely right, Nicole. For example, Germany, Spain, and several other European countries follow this model. The industry sets the standards, and the obligation comes from association membership, not national law.

13:17Nicole Liffrig Molife: That's an important distinction. And beyond national trade associations, are there European-wide industry organizations that require members to report their interactions with healthcare professionals, healthcare organizations, and patient organizations?

13:34Unidentified speaker (speaker_1): Absolutely. And the most notable example there is FBIA, the European Federation. of Pharmaceutical Industries and Associations. So FBI has rules on both disclosure and ethics, and members have to disclose certain reportable activities every year.

13:48Nicole Liffrig Molife: Another practical takeaway: review every industry association your company belongs to at both a national and European level, and confirm you're meeting each one's self-reporting rules.

14:02Unidentified speaker (UNKNOWN): So

14:02Nicole Liffrig Molife: let's recap your tips so far, Evelyn. First, map your footprint. List every country where you market products or work with healthcare professionals, healthcare, and patient organizations. Second, know where your obligation comes from. For each country, find out whether reporting is required by law, like in France or Belgium, or by industry association membership, like in Germany and Spain. Third, check your membership. Review every national and European association your company belongs to, and confirm you're meeting that association's disclosure and ethics rules. Now, Evelyn, let's hop across the channel. How does the UK compare?

14:44Unidentified speaker (speaker_1): Well, the UK is quite different from France, as there is currently no legislative framework regulating transparency. for pharmaceutical and medtech companies. So instead, there are self-regulatory codes, most notably the ABPI code from the Association of the British Pharmaceutical Industry. And so ABPI members self-report under that code, and others can implement it also voluntarily.

15:06Nicole Liffrig Molife: But that might be changing, right?

15:09Unidentified speaker (speaker_1): Well, it it could. There's been an effort to develop legislation to codify these requirements. However, following a public consultation, the government seems to have opted for a guidance based approach and announced the intention to develop and publish clear guidance on best practices for industry in disclosing payments. So it's definitely one to watch.

15:28Nicole Liffrig Molife: That's very helpful. So what has to be disclosed under the industry code?

15:33Unidentified speaker (speaker_1): At a high level, it covers arrangements with healthcare professionals, healthcare organizations. other relevant decision makers, patient organizations, and members of the public. And then for healthcare professionals and healthcare organizations, what must be disclosed is any direct or indirect transfer of value, whether in cash and kind or otherwise, made, whether for promotional purposes or not, in connection with the development or sale of medicines. So that includes things like collaborative and joint. working, donations and grants, fees and expenses for contracted services, support for attendance at events, and sponsorship. Companies also disclose patient organization donations, grants, sponsorship, and contracted services, as well as certain contracted services with members of the public, like speaking at meetings or participating in advisory boards.

16:23Nicole Liffrig Molife: That's quite a list. And how about time? timing? When do companies need to make these reports?

16:30Unidentified speaker (speaker_1): So, unlike France, and probably more like the US, the UK reports annually. Each reporting period covers a full calendar year. Disclosures are due within six months after year end, and they're published at the end of June on the Disclosure UK website. Disclosures are made, good for our American friends, in English, using the template on the PMCPA website, and they stay publicly. public for three years.

16:52Nicole Liffrig Molife: That's very helpful. And Evelyn, could you give us an overview of the consequences or enforcement for not complying?

16:59Unidentified speaker (speaker_1): Sure. The Prescription Medicines Code of Practice Authority, or briefly the PMCPA, can sanction ABPI members through administrative costs, public censure, and for particularly serious breaches, the suspension or even expulsion from the ABPI. And all these education adjudications are made public. Breaches involving interactions with healthcare professionals can also raise bribery concerns, and failing to manage conflicts of interests can lead to fraud proceedings under the Fraud Act of 2006.

17:27Nicole Liffrig Molife: So even where the rules are self-regulatory, there can be real consequences in the UK. That's important for our listeners to know. Evelyn, we've covered a lot of ground today, both for Europe. European life sciences companies and for U.S. companies already doing business in Europe or planning to launch there. We've talked about what is covered in France, the broad range of healthcare beneficiaries, what needs to be reported, the deadlines, and the penalties. And we've also taken a quick look at the rules of the road to identify issues for other European countries. So here's our final. pro tip. Start early. Map out your relationships, your commercial plans, and your industry relationships. So you know exactly which requirements apply to your European operations.

18:15Unidentified speaker (speaker_1): Wow, we really did cover a lot, Nicole. Thanks for having me.

18:19Nicole Liffrig Molife: Evelyn, thank you so much for sharing your insights and tips. I have learned a ton, and I know our listeners did too. And next time I'm in Paris, we need to toast, launching this episode. So where are we going to dinner to celebrate?

18:33Unidentified speaker (UNKNOWN): Well,

18:33Unidentified speaker (speaker_1): it's been a real pleasure, Nicole. And for dinner, let's go to Le Bon Georges. Great food, but even more importantly, the most extensive wine list of Paris.

18:43Nicole Liffrig Molife: I can't wait. I'll see you in Paris soon. And thanks to all of you listening to our Connected with Latham podcast. Stay tuned for more episodes in our Shining a Light on the Sunshine Act and Transparency Requirements series. You can subscribe and listen to new and archived episodes of Latham's podcasts on LW.com, Apple Podcasts, Spotify, or anywhere else you listen to podcasts. If you have any questions or would like additional information, information, please email us using the links located in the show description. We hope you'll join us again next time.

19:23Unidentified speaker (speaker_1): This podcast is provided as a service of Latham Watkins LLP. Listening to this podcast does not create an attorney-client relationship between you and Latham and Watkins LLP, and you should not send confidential information to Latham and Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things. And you may not rely on this podcast as a substitute for legal research andor consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise you on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified

20:02Unidentified speaker (UNKNOWN): attitude.

20:03Unidentified speaker (speaker_1): attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under the New York's disciplinary rules to Latham and Watkins LLP. 1271. Avenue of the Americas. New York, New York, 10020. Phone number 1212-906-1200.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights